• The Dual Advantage: Improving Alzheimer Care with Combination Therapy - Frankly Speaking Ep 399

  • Sep 23 2024
  • Durée: 10 min
  • Podcast

The Dual Advantage: Improving Alzheimer Care with Combination Therapy - Frankly Speaking Ep 399

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-399

    Overview: In this episode, we look at a new study showing increased probability of survival for patients with Alzheimer disease (AD) who take donepezil and memantine together. We review current treatments for AD and address common hesitations in prescribing dual pharmacotherapy, providing vital insights for primary care clinicians.

    Episode resource links:

    • Yaghmaei, E., Lu, H., Ehwerhemuepha, L. et al. Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer’s disease patients.Commun Med 4, 99 (2024). https://doi.org/10.1038/s43856-024-00527-6
    • Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. PMID: 32914577; PMCID: PMC7667299.

    Guest: Jillian Joseph, MPAS, PA-C

    Music Credit: Matthew Bugos

    Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com

    Voir plus Voir moins
activate_samplebutton_t1
Science
Voir plus Voir moins

Ce que les auditeurs disent de The Dual Advantage: Improving Alzheimer Care with Combination Therapy - Frankly Speaking Ep 399

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.